Interested in Helping to Develop a Non-Invasive Way to Measure Blood Flow to the Head? If you are a woman between the ages of 18-65 and you have myalgic encephalomyelitis (ME) or you are healthy, you may be eligible to participate in a study. conta.cc/4Ale4cN #MECFS @sunsopeningband.bsky.social

New RCT of a valacyclovir, celecoxib, and nirmatrelvir/ritonavir combo for Long Covid starting at Mount Sinai. Phase 2, enrolling 150 people. Builds on this open-label case series: www.frontiersin.org/journals/imm...

PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment

TUSCALOOSA, Ala., Sept. 24, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics, LLC, a clinical-stage biopharmaceutical company developing combinatio...

markets.businessinsider.com

🚨Important: Dr. Nancy Klimas’ sipavibart trial needs to enroll 5 more Long COVID participants by of this month! Details: 👇 www.reddit.com/r/covidlongh...

From the covidlonghaulers community on Reddit: Sipavibart trial run by Nancy Klimas needs 5 more Long COVID enrollees by the end of the month

Posted by LRay_007 - 95 votes and 30 comments

reddit.com

5) The primary outcome was the Brief Pain Inventory-Short Form (BPI-SF), which measures not only pain but also the impact on various activities and aspects of life. The treatment group improved by 0.5 out of range of 10 points, which wasn't statistically significant.

1) The team of Andreas Goebel was the first to transfer autoantibodies of fibromyalgia patients to mice (similar studies later followed in Long Covid). In this paper, they tested rozanolixizumas: a drug that lowers circulating antibody levels. A brief summary of the results 👇

1) The pharma company BioVie announced the results of the phase 2 trial of their drug Bezisterim for Long Covid. Although the primary analysis showed no significant effect, an analysis in subgroups with a great symptom burden suggested an improvement. A brief breakdown 👇

Now they're initiating trials using anti-CD38 and anti-CD14 antibodies, with some promising results. This one was unfortunately quite a lot, referenced a large number of publications-- sorry I could not hunt them down fast enough! Remember the recording will be out there in a week or so, likely.

Rob is hoping to present results on this trial next year:

“It is no longer the science, Dr. Hong believes, that is holding back potential cures, but our capacity to try new medicines in clinical trials.” www.nytimes.com/2026/09/04/o...

Opinion | The Search for New Cures Is Broken (Gift Article)

It is too hard for medical researchers to launch clinical trials.

nytimes.com

1) Very sad news that Jo Cambridge has passed away. She was a Prof. in rheumatology who pioneered B-cell depletion therapy in autoimmune diseases together with Jonathan Edwards. But she also did several useful studies on ME/CFS and was much loved in the community.

1) Unfortunately, another negative result for immunoadsorption for Long Covid. A small trial that focused only on patients with elevated levels of antibodies against β1/β2-adrenergic and/or M3/M4-muscarinic acetylcholine receptors found no improvement in objective outcomes.

3) The trial also focuses on a very specific subset of ME/CFS patients with elevated antibodies against β2-adrenergic receptors and "a pro-inflammatory immune cell status."

2) Inebilizumab targets the CD19 a marker on B-cells; the immune cells that produce antibodies. Compared to Rituximab (which targets CD20), inebilizumab targets a broader range of B-cell subsets, including early B cells and plasmablasts.

1) 🇩🇪 There's now more info about the PIONEER study which will test inebilizumab (a drug that targets B-cells), in a subgroup of ME/CFS patients. It's a randomised trial at the Charité that aims to include 38 participants.

Vrije Universiteit Amsterdam, 105 participants. Long COVID and ME/CFS muscles had impaired mitochondrial energy production and fewer capillaries for their size, unlike 60 days of bed rest. Inactivity alone did not explain this. www.nature.com/articles/s41...

2) The treatment trial is led by Carmen Scheibenbogen and will be a follow-up study to the randomized Phase II trial of the CD19 antibody inebilizumab. Tafasitamab also targets CD19 but is less expensive, so they want to test if this also works in a subgroup of 38 patients.

1) 🇩🇪 The German ME/CFS Research Foundation has supported 7 research projects with a total budget of € 2.4 million. It includes a treatment trial of tafasitamab, which targets B-cells, and a genetic study of families with multiple members affected by ME/CFS A brief overview

If you were a participant in the Vyvgart trial, please email Mackenzie at coreresearch@mountsinai.org to get a free at-home lab kit. Mt. Sinai & Yale are testing against a newly discovered autoimmune biomarker, with the goal of initiating a new FCRN inhibitor trial by year-end!

9) Link to the paper: Acanfora et al. 2026. Vagal cholinergic denervation of the gastric mucosa in Long-COVID-19: in vivo evidence of structural autonomic dysfunction.

Vagal cholinergic denervation of the gastric mucosa in Long-COVID-19: in vivo evidence of structural autonomic dysfunction

Dysautonomia has been increasingly recognized as a key feature of Long-COVID-19, potentially contributing to persistent gastrointestinal and systemic …

sciencedirect.com

1) 🇮🇹 An Italian hospital showed reduced nerves in the gastric lining of Long Covid patients compared to controls. It was a preliminary study though, with only 12 patients and 8 controls.

9) Link to the paper: Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial www.thelancet.com/jo...

2) The graph below shows the main findings. Unfortunately, there wasn't a placebo control group only a group that received no drug, only usual care. The primary outcome was the Fatigue Assessment Scale (FAS, range: 10-50), with higher scores indicating worse fatigue.

1) 🇬🇧 The results of the big STIMULATE-ICP study are in. It tested three repurposed drugs in hundreds of Long Covid patients: - colchicine: an anti-inflammatory - famotidine and loratadine: antihistamines - rivaroxaban: an anticoagulant Sadly, all three had poor results.

By itself, administered subcutaneously. clinicaltrials.gov/study/NCT071...

Anktiva at UCSF

well, it happened: i have now taken cancer drugs (as part of a clinical trial) to see what they do for my long covid.

Geneva University Hospitals, 203 people. Temelimab targeted HERV-W ENV, a proposed immune trigger in Long COVID, but did not improve fatigue, cognition, function, or biomarkers versus placebo after 24 weeks. www.sciencedirect.com/science/arti...

Temelimab versus placebo in patients with post-COVID condition

More than 400 million individuals are estimated to have been affected by post-COVID condition or long COVID. This condition can lead to significantly …

sciencedirect.com

Oh no, I spent forever waiting for the video of Dr. Fluge’s daratumumab trial update at the International ME/CFS Conference 2026 to be uploaded, and now it looks like it won’t be at all. Bummer, I was really looking forward to watching that! events.mecfs-research.org/en/events/co...

8 ) More info about the inclusion criteria and how to participate can be found in this article by the ME Association:

Research: Does poor oxygenation and a delay in muscle energy recovery contribute to fatigue and PEM in ME/CFS? Now Recruiting!  - The ME Association

The ME Association is pleased to confirm that Stage 1 […]

meassociation.org.uk

1) 🇬🇧 The ME Association is recruiting patients for a study that will test oxygenation and energy recovery in the calf muscles of ME/CFS patients. The study will use non-invasive technologies such as magnetic resonance imaging (MRI) and near-infrared spectroscopy (NIRS).